Orange Book product · Generic (ANDA)
RITONAVIR
RITONAVIR
At a glance
Sep 17, 2018
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Sep 17, 2018
7 yr 10 mo ago
Today
Pharmaceutical detail
Active ingredient
RITONAVIR
Strength
100MG
Dosage form
TABLET
Route
ORAL
TE code
AB
Application
ANDA 204587
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of RITONAVIR
- 2017NORVIRBrand (NDA)
NDA 209512 · ABBVIE
- 2010NORVIRBrand (NDA)
NDA 022417 · ABBVIE
- 1999NORVIRBrand (NDA)
NDA 020945 · ABBVIE
- 1996NORVIRBrand (NDA)
NDA 020680 · ABBOTT
- 1996NORVIRBrand (NDA)
NDA 020659 · ABBVIE
- 2024RITONAVIRGeneric (ANDA)
ANDA 205024 · QUAGEN
- 2022RITONAVIRGeneric (ANDA)
ANDA 203759 · CIPLA
- 2020RITONAVIRGeneric (ANDA)
ANDA 205801 · HIKMA
- 2018RITONAVIRGeneric (ANDA)
ANDA 208890 · AMNEAL
- 2018RITONAVIRGeneric (ANDA)
ANDA 206614 · AUROBINDO PHARMA LTD
- 2015RITONAVIRGeneric (ANDA)
ANDA 202573 · CIPLA
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
